vs
Side-by-side financial comparison of BALCHEM CORP (BCPC) and CareTrust REIT, Inc. (CTRE). Click either name above to swap in a different company.
BALCHEM CORP is the larger business by last-quarter revenue ($263.6M vs $134.9M, roughly 2.0× CareTrust REIT, Inc.). CareTrust REIT, Inc. runs the higher net margin — 82.5% vs 14.9%, a 67.6% gap on every dollar of revenue. On growth, CareTrust REIT, Inc. posted the faster year-over-year revenue change (55.1% vs 9.8%). Over the past eight quarters, CareTrust REIT, Inc.'s revenue compounded faster (46.2% CAGR vs 4.9%).
Balchem Corp is a global specialty chemicals and nutritional ingredients provider that develops, manufactures and distributes application-specific products for human nutrition, animal health, pharmaceutical and industrial end markets, serving customers across North America, Europe and Asia Pacific.
CareTrust REIT, Inc.CTREEarnings & Financial Report
Target Healthcare REIT is a British property investment company which invests in healthcare properties and holds a large portfolio of care homes. It is structured as a real estate investment trust (REIT) and is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
BCPC vs CTRE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $263.6M | $134.9M |
| Net Profit | $39.2M | $111.3M |
| Gross Margin | 35.6% | — |
| Operating Margin | 19.8% | — |
| Net Margin | 14.9% | 82.5% |
| Revenue YoY | 9.8% | 55.1% |
| Net Profit YoY | 16.8% | 113.5% |
| EPS (diluted) | $1.21 | $0.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $263.6M | $134.9M | ||
| Q3 25 | $267.6M | $132.4M | ||
| Q2 25 | $255.5M | $112.5M | ||
| Q1 25 | $250.5M | $96.6M | ||
| Q4 24 | $240.0M | $86.9M | ||
| Q3 24 | $239.9M | $77.4M | ||
| Q2 24 | $234.1M | $68.9M | ||
| Q1 24 | $239.7M | $63.1M |
| Q4 25 | $39.2M | $111.3M | ||
| Q3 25 | $40.3M | $74.9M | ||
| Q2 25 | $38.3M | $68.5M | ||
| Q1 25 | $37.1M | $65.8M | ||
| Q4 24 | $33.6M | $52.1M | ||
| Q3 24 | $33.8M | $33.4M | ||
| Q2 24 | $32.1M | $10.8M | ||
| Q1 24 | $29.0M | $28.7M |
| Q4 25 | 35.6% | — | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 36.4% | — | ||
| Q1 25 | 35.2% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 35.6% | — | ||
| Q2 24 | 35.5% | — | ||
| Q1 24 | 34.0% | — |
| Q4 25 | 19.8% | — | ||
| Q3 25 | 20.4% | 58.1% | ||
| Q2 25 | 20.1% | 61.3% | ||
| Q1 25 | 20.4% | — | ||
| Q4 24 | 19.8% | — | ||
| Q3 24 | 20.0% | 43.0% | ||
| Q2 24 | 19.6% | 15.1% | ||
| Q1 24 | 17.4% | — |
| Q4 25 | 14.9% | 82.5% | ||
| Q3 25 | 15.1% | 56.6% | ||
| Q2 25 | 15.0% | 60.9% | ||
| Q1 25 | 14.8% | 68.1% | ||
| Q4 24 | 14.0% | 60.0% | ||
| Q3 24 | 14.1% | 43.2% | ||
| Q2 24 | 13.7% | 15.6% | ||
| Q1 24 | 12.1% | 45.6% |
| Q4 25 | $1.21 | $0.52 | ||
| Q3 25 | $1.24 | $0.35 | ||
| Q2 25 | $1.17 | $0.35 | ||
| Q1 25 | $1.13 | $0.35 | ||
| Q4 24 | $1.03 | $0.30 | ||
| Q3 24 | $1.03 | $0.21 | ||
| Q2 24 | $0.98 | $0.07 | ||
| Q1 24 | $0.89 | $0.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $74.6M | $198.0M |
| Total DebtLower is stronger | — | $894.2M |
| Stockholders' EquityBook value | $1.3B | $4.0B |
| Total Assets | $1.7B | $5.1B |
| Debt / EquityLower = less leverage | — | 0.22× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $74.6M | $198.0M | ||
| Q3 25 | $65.1M | $712.5M | ||
| Q2 25 | $65.4M | $306.1M | ||
| Q1 25 | $49.9M | $26.5M | ||
| Q4 24 | $49.5M | $213.8M | ||
| Q3 24 | $73.7M | $377.1M | ||
| Q2 24 | $63.7M | $495.1M | ||
| Q1 24 | $60.3M | $451.2M |
| Q4 25 | — | $894.2M | ||
| Q3 25 | — | $893.8M | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $822.1M | ||
| Q4 24 | — | $396.9M | ||
| Q3 24 | — | $396.7M | ||
| Q2 24 | — | $671.1M | ||
| Q1 24 | — | $595.9M |
| Q4 25 | $1.3B | $4.0B | ||
| Q3 25 | $1.3B | $4.0B | ||
| Q2 25 | $1.3B | $3.3B | ||
| Q1 25 | $1.2B | $2.9B | ||
| Q4 24 | $1.1B | $2.9B | ||
| Q3 24 | $1.2B | $2.4B | ||
| Q2 24 | $1.1B | $1.9B | ||
| Q1 24 | $1.1B | $1.7B |
| Q4 25 | $1.7B | $5.1B | ||
| Q3 25 | $1.7B | $5.1B | ||
| Q2 25 | $1.7B | $4.7B | ||
| Q1 25 | $1.6B | $3.9B | ||
| Q4 24 | $1.6B | $3.4B | ||
| Q3 24 | $1.6B | $2.9B | ||
| Q2 24 | $1.6B | $2.7B | ||
| Q1 24 | $1.6B | $2.3B |
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.22× | ||
| Q2 25 | — | 0.35× | ||
| Q1 25 | — | 0.28× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.16× | ||
| Q2 24 | — | 0.35× | ||
| Q1 24 | — | 0.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $67.3M | $394.0M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.72× | 3.54× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $67.3M | $394.0M | ||
| Q3 25 | $65.6M | $100.9M | ||
| Q2 25 | $47.3M | $100.8M | ||
| Q1 25 | $36.5M | $71.4M | ||
| Q4 24 | $52.3M | $244.3M | ||
| Q3 24 | $51.3M | $67.2M | ||
| Q2 24 | $45.0M | $53.0M | ||
| Q1 24 | $33.4M | $48.8M |
| Q4 25 | 1.72× | 3.54× | ||
| Q3 25 | 1.63× | 1.35× | ||
| Q2 25 | 1.23× | 1.47× | ||
| Q1 25 | 0.98× | 1.08× | ||
| Q4 24 | 1.56× | 4.68× | ||
| Q3 24 | 1.52× | 2.01× | ||
| Q2 24 | 1.40× | 4.92× | ||
| Q1 24 | 1.15× | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCPC
| Human Nutrition And Health | $166.1M | 63% |
| Animal Nutrition And Health | $61.2M | 23% |
| Specialty Products | $34.8M | 13% |
CTRE
Segment breakdown not available.
